Acquisition - Narrative (Details)		3 Months Ended		7 Months Ended	9 Months Ended
	Nov. 24, 2021 USD ($) right $ / shares	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Contingent consideration		$ 57,371,000			$ 57,371,000	$ 80,477,000
Deferred income tax liabilities adjustments					$ 1,800,000
Income tax expense (benefit), adjustment of deferred tax (asset) liability		$ (1,900,000)	$ 3,700,000
Adamas Pharmaceuticals
Business Acquisition [Line Items]
Cash consideration paid	$ 400,806,000
Contingents value rights | right	2
Rights per share (in dollars per share) | $ / shares	$ 0.50
Additional cash payments upon milestone achievements minimum	$ 150,000,000
Additional cash payments upon milestone achievements maximum	225,000,000
Contingent consideration	10,300,000
Additional cash payments upon milestone achievements minimum	0
Additional cash payments upon milestone achievements maximum	$ 50,900,000
Deferred income tax liabilities adjustments				$ 1,753,000